ArticleInvestigative ophthalmology & visual science2025
Retinal Impairments in Mice Lacking Both Nxnl1 and Nxnl2 Genes.
Article in Investigative ophthalmology & visual science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The protein products of the nucleoredoxin-like 1 (Nxnl1) gene have been proposed for their potential therapeutic benefit in retinitis pigmentosa (RP). Nxnl1 encodes two isoforms: rod-derived viability factor (RdCVF), which supports cone photoreceptor survival, and RdCVFL, which mitigates oxidative stress. Similarly, Nxnl2, a paralog of Nxnl1, encodes RdCVF2 and RdCVF2L, which also have photoreceptor protective properties. This study aimed to investigate whether the simultaneous disruption of Nxnl1 and Nxnl2 results in a more severe retinal phenotype on photoreceptor status compared to the disruption of either gene individually. Methods: Double Nxnl1-/-Nxnl2-/- mice were generated, and their retinal phenotype was compared to Nxnl1-/-, Nxnl2-/-, and Nxnl1+/+Nxnl2+/+ mice using spectral-domain optical coherence tomography (SD-OCT), fundus imaging, electroretinography (ERG), and immunofluorescence for retinal structure and cone density assessment. Results: In Nxnl1-/-Nxnl2-/- mice, SD-OCT revealed a significant reduction in outer nuclear layer (ONL) thickness at 3, 6, and 12 months of age. Rod dysfunction was observed at all ages with a significant decrease in both a- and b-wave amplitudes of the scotopic ERG. Although photopic single-flash and flicker ERGs remained normal, cone density was significantly reduced at 12.5 months of age. Additionally, retinal immunostaining confirmed impairments in both rod and cone photoreceptors. Conclusions: Nxnl1-/-Nxnl2-/- mice showed more severe structural and functional retinal deficits compared to the other groups at all ages, indicating that Nxnl1 and Nxnl2 exert non-redundant and/or complementary roles in maintaining photoreceptor function. These findings suggest that the combined products of Nxnl genes may yield more effective therapies for RP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.